AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Moreover, 15% of them were taking LAMA or LABA therapies in combination with inhaled corticosteroids ... company's lead drug candidate into the large COPD market in late 2023 or 2024.
Healthshots on MSN15h
HMPV in women: Can there be complications during pregnancy?Human metapneumovirus (hMPV) is a viral infection that has spread across the globe and has led to concerns among health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback